thymosin beta-4 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-16 and is reviewed periodically as new material appears.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
=== Tolerance === LSD shows significant tachyphylaxis, with tolerance developing 24 hours after administration. The progression of tolerance at intervals shorter than 24 hours remains largely unknown. Tolerance typically resets to baseline after 3–4 days of abstinence. Significant cross-tolerance occurs between LSD, mescaline and psilocybin. A slight cross-tolerance to DMT is observed in humans highly tolerant to LSD. Tolerance to LSD also builds up with consistent use, and is believed to result from serotonin 5-HT2A receptor downregulation. Researchers believe that tolerance returns to baseline after two weeks of not using psychedelics.
=== 2010 census === The 2010 United States census counted 8,573 people, 3,002 households, and 2,318 families in the borough. The population density was 4,154.5 per square mile (1,604.1/km2). There were 3,114 housing units at an average density of 1,509.0 per square mile (582.6/km2). The racial makeup was 68.95% (5,911) White, 0.73% (63) Black or African American, 0.03% (3) Native American, 27.64% (2,370) Asian, 0.01% (1) Pacific Islander, 1.07% (92) from other races, and 1.55% (133) from two or more races. Hispanic or Latino of any race were 6.26% (537) of the population. Korean Americans accounted for 17.8% of the population. Of the 3,002 households, 40.5% had children under the age of 18; 66.2% were married couples living together; 7.9% had a female householder with no husband present and 22.8% were non-families. Of all households, 21.1% were made up of individuals and 15.4% had someone living alone who was 65 years of age or older. The average household size was 2.84 and the average family size was 3.32. Same-sex couples headed 7 households in 2010, an increase from the 5 counted in 2000. 26.8% of the population were under the age of 18, 5.4% from 18 to 24, 20.6% from 25 to 44, 29.8% from 45 to 64, and 17.4% who were 65 years of age or older. The median age was 43.7 years. For every 100 females, the population had 88.6 males. For every 100 females ages 18 and older there were 85.7 males.
The oldest-known fossil among the Eutheria ("true beasts") is the small shrewlike Juramaia sinensis, or "Jurassic mother from China", dated to 160 million years ago in the late Jurassic. A later eutherian relative, Eomaia, dated to 125 million years ago in the early Cretaceous, possessed some features in common with the marsupials but not with the placentals, evidence that these features were present in the last common ancestor of the two groups but were later lost in the placental lineage. In particular, the epipubic bones extend forwards from the pelvis. These are not found in any modern placental, but they are found in marsupials, monotremes, other nontherian mammals and Ukhaatherium, an early Cretaceous animal in the eutherian order Asioryctitheria. This also applies to the multituberculates. They are apparently an ancestral feature, which subsequently disappeared in the placental lineage. These epipubic bones seem to function by stiffening the muscles during locomotion, reducing the amount of space being presented, which placentals require to contain their fetus during gestation periods. A narrow pelvic outlet indicates that the young were very small at birth and therefore pregnancy was short, as in modern marsupials. This suggests that the placenta was a later development. One of the earliest-known monotremes was Teinolophos, which lived about 120 million years ago in Australia.
== Disorders == When there are insufficient nutrient minerals or osteoblast dysfunction, the osteoid does not mineralize properly and accumulates. The resultant disorder is termed rickets in children and osteomalacia in adults. A deficiency of type I collagen, such as in osteogenesis imperfecta, also leads to defective osteoid and brittle, fracture-prone bones. In some cases, secondary hyperparathyroidism can cause a disturbance in mineralisation of calcium and phosphate. Another condition is a disturbance in primitive transformed cells of mesenchymal origin, which exhibit osteoblastic differentiation and produce malignant osteoid. This results in the formation of a malignant primary bone tumor known as osteosarcoma or osteogenic sarcoma. This malignancy most often develops in adolescence during periods of rapid osteoid formation (commonly referred to as growth spurts).
=== Russia === Russia has a plan for increasing its fleet of fast breeder reactors significantly. A BN-800 reactor (800 MWe) at Beloyarsk was completed in 2012, succeeding a smaller BN-600. It reached its full power production in 2016. Plans for the construction of a larger BN-1200 reactor (1,200 MWe) was scheduled for completion in 2018, with two additional BN-1200 reactors built by the end of 2030. However, in 2015 Rosenergoatom postponed construction indefinitely to allow fuel design to be improved after more experience of operating the BN-800 reactor, and among cost concerns. In January 2026, Rosatom reported that preparations had begun for Beloyarsk Unit 5, using the BN-1200M sodium-cooled fast reactor. Construction of the lead-cooled BREST-OD-300 reactor at the Siberian Chemical Combine in Seversk began in June 2021. The BREST (Russian: bystry reaktor so svintsovym teplonositelem, English: fast reactor with lead coolant) design is seen as a successor to the BN series and the 300 MWe unit at the SCC could be the forerunner to a 1,200 MWe version for wide deployment as a commercial power generation unit. The development program is as part of an Advanced Nuclear Technologies Federal Program 2010–2020 that seeks to exploit fast reactors for uranium efficiency while 'burning' radioactive substances that would otherwise be disposed of as waste. Its core would measure about 2.3 metres in diameter by 1.1 metres in height and contain 16 tonnes of fuel. The unit would be refuelled every year, with each fuel element spending five years in total within the core.
Sources: en.wikipedia.org
Gas phase regioselectivity is calculated to favor 1,5 addition over 1,4 addition by up to 2.9 kcal/mol in activation energy in the gas phase; solvation corrections give the same energy barriers for both regioisomers, explaining the regioisomeric mix that results from DIFO cycloadditions. While the 1,4 isomer is disfavored by its larger dipole moment (all electron-rich substituents on one side), solvation stabilizes it more strongly than the 1,5 isomer, eroding regioselectivity. Experimental studies by Carolyn R. Bertozzi report a nearly 1:1 ratio of regioisomers, confirming the predicted lack of regioselectivity in the addition. Furthermore, nearly all of the distortion energy (92%) arises from the distortion of the 1,3 dipole rather than the cyclooctyne, which has a pre-distorted ground state geometry that increases its reactivity. Fluorination decreases the distortion energy by allowing the transition state to be achieved with a lesser distortion of the 1,3-dipole during a reaction, resulting in a larger dipole angle.
Some publications write the nucleotides in a different order (e.g., some authors choose to group two purines together and the two pyrimidines together; see also models of DNA evolution). These differences in notation make it important to be clear regarding the order of the states when writing the
== Advantages == SMB provides lower production cost by requiring less column volume, less chromatographic separation media ("packing" or "stationary phase"), using less solvent and less energy, and requiring far less labor. At industrial scale an SMB chromatographic separator is operated continuously, requiring less resin and less solvent than batch chromatography. The continuous operation facilitates operation control and integration into production plants.
See the Bombers fly up, up! To win the premiership flag. Our boys who play this grand old game, Are always striving for glory and fame! See the Bombers fly up, up, The other teams they don't fear; They all try their best, But they can't get near, As the Bombers fly up! Songwriter Mike Brady, of "Up There Cazaly" fame, penned an updated version of the song in 1999 complete with a new verse arrangement, but it was not well received. However, this version is occasionally played at club functions. In 2018, Andrews revealed that there was an error in the lyrics, in which in the line "The other teams they don't fear", the word "they" was supposed to be "we".
=== Disease === One of the major causes of amputation in medieval Europe was disease. Ergotism (also known as Saint-Anthony's fire) was a fungus found in rye that caused gangrene that spread from the fingers and toes. If the tissue death from the disease was severe enough, the limb would spontaneously fall off on its own without blood loss.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.